T. Rowe Price Investment Management, Inc. Rapt Therapeutics, Inc. Transaction History

T. Rowe Price Investment Management, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$11.28 - $25.46 $292,930 - $661,170	25,969 Added 2.07%	1,277,861 $31.8 Million
Q3 2023 Nov 14, 2023	BUY	$16.34 - $24.66 $152,043 - $229,461	9,305 Added 0.75%	1,251,892 $20.8 Million
Q2 2023 Aug 14, 2023	BUY	$16.06 - $21.61 $173,512 - $233,474	10,804 Added 0.88%	1,242,587 $23.2 Million
Q1 2023 May 15, 2023	SELL	$17.19 - $30.8 $274,197 - $491,290	-15,951 Reduced 1.28%	1,231,783 $22.6 Million
Q4 2022 Feb 14, 2023	BUY	$16.28 - $24.6 $49,865 - $75,349	3,063 Added 0.25%	1,247,734 $24.7 Million
Q3 2022 Nov 14, 2022	BUY	$17.96 - $30.46 $22.4 Million - $37.9 Million	1,244,671 New	1,244,671 $29.9 Million

104

27.1M

26.7K

2.4K

Ticker RAPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,656,600
Market Cap $26.1M
Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...

Get notified when there are updates to the investment portfolio of T. Rowe Price Investment Management, Inc., based on Form 13F filings with the SEC.

Stay updated on T. Rowe Price Investment Management, Inc. with notifications on news.